Scholarlink

<p>Melanoma remains one of the most aggressive cutaneous malignancies, accounting for a disproportionate share of skin cancer-related mortality despite relatively lower incidence. Over the past decade, immune checkpoint inhibitors (ICIs) have revolutionized melanoma management, with dual blockade of programmed death receptor-1 (PD-1) and cytotoxic T-lymphocyte–associated protein-4 (CTLA-4) representing one of the most impactful therapeutic advances. This narrative review critically examines the clinical integration of nivolumab–ipilimumab (Nivo-Ipi) combination therapy across metastatic, neoadjuvant, and adjuvant melanoma settings, with emphasis on efficacy, safety, and emerging clinical challenges.&#xa0;Evidence from pivotal randomized trials, particularly the 10-year final outcomes of CheckMate 067, demonstrates that Nivo-Ipi confers substantial improvements in overall survival compared with ipilimumab monotherapy, and numerically superior outcomes compared with nivolumab monotherapy—though the trial was not powered to formally establish this latter comparison. Landmark analyses reveal durable survival plateaus extending beyond seven years in approximately 31% of combination-treated patients, redefining expectations for advanced melanoma. However, this enhanced efficacy is accompanied by significantly higher rates of immune-related adverse events (irAEs), necessitating careful patient selection and proactive toxicity management. Emerging data from the NADINA trial establish a compelling neoadjuvant role for the combination, while the adjuvant CheckMate 915 trial failed to demonstrate recurrence-free survival benefit over nivolumab monotherapy. Future progress will depend on biomarker-driven personalization, refined sequencing strategies, and integration of the combination within an increasingly competitive first-line landscape that now includes nivolumab plus relatlimab.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nivolumab and ipilimumab combination therapy for melanoma efficacy, safety and clinical integration in metastatic and adjuvant settings

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月21日

查看全文
  • Rechner Afuh,
  • Patrick Ashinze,
  • Suvam Banerjee,
  • Emmanuel Egbunu,
  • Matthew Olamide Olaniyan,
  • Ayodele Blessing Ayo-ige,
  • Eniola Kabirat Soyinka,
  • Ahmad Olawale Atere,
  • Stephen Igwe,
  • Yetunde Morayo Oladipupo,
  • Ayomide Obaoye,
  • Yisa Nasiru,
  • Caleb Aboderin,
  • Stephen Olowookere

摘要

Melanoma remains one of the most aggressive cutaneous malignancies, accounting for a disproportionate share of skin cancer-related mortality despite relatively lower incidence. Over the past decade, immune checkpoint inhibitors (ICIs) have revolutionized melanoma management, with dual blockade of programmed death receptor-1 (PD-1) and cytotoxic T-lymphocyte–associated protein-4 (CTLA-4) representing one of the most impactful therapeutic advances. This narrative review critically examines the clinical integration of nivolumab–ipilimumab (Nivo-Ipi) combination therapy across metastatic, neoadjuvant, and adjuvant melanoma settings, with emphasis on efficacy, safety, and emerging clinical challenges. Evidence from pivotal randomized trials, particularly the 10-year final outcomes of CheckMate 067, demonstrates that Nivo-Ipi confers substantial improvements in overall survival compared with ipilimumab monotherapy, and numerically superior outcomes compared with nivolumab monotherapy—though the trial was not powered to formally establish this latter comparison. Landmark analyses reveal durable survival plateaus extending beyond seven years in approximately 31% of combination-treated patients, redefining expectations for advanced melanoma. However, this enhanced efficacy is accompanied by significantly higher rates of immune-related adverse events (irAEs), necessitating careful patient selection and proactive toxicity management. Emerging data from the NADINA trial establish a compelling neoadjuvant role for the combination, while the adjuvant CheckMate 915 trial failed to demonstrate recurrence-free survival benefit over nivolumab monotherapy. Future progress will depend on biomarker-driven personalization, refined sequencing strategies, and integration of the combination within an increasingly competitive first-line landscape that now includes nivolumab plus relatlimab.